Sign In
Buy ALGS
$5.14
-0.110 (-2.10%)
At Close: Jun 03, 2026
Aligos Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
04:05pm, Tuesday, 21'st Dec 2021
SOUTH SAN FRANCISCO, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address
Aligos Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
08:00am, Monday, 22'nd Nov 2021
SOUTH SAN FRANCISCO, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address
All You Need to Know About Aligos Therapeutics, Inc. (ALGS) Rating Upgrade to Buy
01:45pm, Tuesday, 09'th Nov 2021
Aligos Therapeutics, Inc. (ALGS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Aligos Therapeutics to Present Data for its Clinical Portfolio Targeting Chronic Hepatitis B and NASH at AASLD'S The Liver Meeting® 2021
04:58pm, Thursday, 14'th Oct 2021
SOUTH SAN FRANCISCO, Calif., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address
Aligos now evaluating three of its four chronic hepatitis B (CHB) portfolio drug candidates in clinical trials Aligos now evaluating three of its four chronic hepatitis B (CHB) portfolio drug candidat
Aligos Therapeutics to Present at the Cantor Virtual Global Healthcare Conference
04:05pm, Monday, 20'th Sep 2021
SOUTH SAN FRANCISCO, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address
Aligos Therapeutics to Announce Second Quarter 2021 Results August 5, 2021
04:05pm, Thursday, 29'th Jul 2021
SOUTH SAN FRANCISCO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address
Aligos Therapeutics Announces Pricing of $83.6 Million Public Offering of Common Stock
10:08pm, Wednesday, 30'th Jun 2021
SOUTH SAN FRANCISCO, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced the pricing of its underwritten public offering of 4,400,000 shares of common st
Aligos Therapeutics Announces Proposed Public Offering of Common Stock
04:10pm, Monday, 28'th Jun 2021
SOUTH SAN FRANCISCO, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced that it has commenced an underwritten public offering of 4,000,000 shares of com
Aligos Therapeutics to Present at the Jefferies Virtual Healthcare Conference
04:05pm, Thursday, 20'th May 2021
SOUTH SAN FRANCISCO, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address u
ALGS Stock: 4.76% Increase Explanation
07:04am, Thursday, 15'th Apr 2021
The stock price of Aligos Therapeutics, Inc. (Nasdaq: ALGS) increased by 4.76% yesterday. This is why it happened.
Aligos now evaluating two of its four Chronic Hepatitis B (CHB) portfolio drug candidates in patients Aligos now evaluating two of its four Chronic Hepatitis B (CHB) portfolio drug candidates in patie
The first drug candidate in Aligos's chronic hepatitis B portfolio to be administered to CHB patients The first drug candidate in Aligos's chronic hepatitis B portfolio to be administered to CHB patie
SOUTH SAN FRANCISCO, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address
Aligos (ALGS) in Focus: Stock Moves 5.6% Higher
09:47am, Thursday, 17'th Dec 2020
Aligos (ALGS) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
